Mike Kratky
Stock Analyst at Leerink Partners
(3.51)
# 909
Out of 4,989 analysts
34
Total ratings
52.38%
Success rate
32.86%
Average return
Main Sectors:
Stocks Rated by Mike Kratky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSP Inspire Medical Systems | Maintains: Market Perform | $116 → $97 | $79.88 | +21.43% | 7 | Aug 15, 2025 | |
| BSX Boston Scientific | Initiates: Outperform | $118 | $97.83 | +20.62% | 1 | Jun 16, 2025 | |
| MDT Medtronic | Initiates: Outperform | $110 | $95.08 | +15.69% | 1 | Jun 16, 2025 | |
| BBNX Beta Bionics | Initiates: Outperform | $28 | $22.46 | +24.67% | 1 | Feb 24, 2025 | |
| TXG 10x Genomics | Downgrades: Market Perform | $25 → $12 | $13.04 | -7.98% | 2 | Feb 13, 2025 | |
| DXCM DexCom | Maintains: Outperform | $90 → $87 | $67.45 | +28.98% | 2 | Oct 25, 2024 | |
| PEN Penumbra | Initiates: Outperform | $263 | $255.60 | +2.90% | 1 | Sep 3, 2024 | |
| TNDM Tandem Diabetes Care | Upgrades: Outperform | $34 → $45 | $12.57 | +258.00% | 2 | Apr 25, 2024 | |
| NPCE NeuroPace | Initiates: Outperform | $22 | $9.94 | +121.33% | 1 | Jan 30, 2024 | |
| PODD Insulet | Initiates: Outperform | $184 | $330.84 | -44.38% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $31.68 | +32.58% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $342 | $438.72 | -22.05% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $75 | $74.41 | +0.79% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $37 | $37.39 | -1.04% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $17.20 | -47.67% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $325 → $50 | $2.87 | +1,645.20% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $45 | $1.43 | +3,046.85% | 2 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $145 → $315 | $439.93 | -28.40% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $26 → $31 | $49.13 | -36.90% | 2 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $14.78 | -5.28% | 1 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $40 | $19.43 | +105.87% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $392 → $384 | $19.86 | +1,833.53% | 1 | Aug 11, 2022 |
Inspire Medical Systems
Aug 15, 2025
Maintains: Market Perform
Price Target: $116 → $97
Current: $79.88
Upside: +21.43%
Boston Scientific
Jun 16, 2025
Initiates: Outperform
Price Target: $118
Current: $97.83
Upside: +20.62%
Medtronic
Jun 16, 2025
Initiates: Outperform
Price Target: $110
Current: $95.08
Upside: +15.69%
Beta Bionics
Feb 24, 2025
Initiates: Outperform
Price Target: $28
Current: $22.46
Upside: +24.67%
10x Genomics
Feb 13, 2025
Downgrades: Market Perform
Price Target: $25 → $12
Current: $13.04
Upside: -7.98%
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $90 → $87
Current: $67.45
Upside: +28.98%
Penumbra
Sep 3, 2024
Initiates: Outperform
Price Target: $263
Current: $255.60
Upside: +2.90%
Tandem Diabetes Care
Apr 25, 2024
Upgrades: Outperform
Price Target: $34 → $45
Current: $12.57
Upside: +258.00%
NeuroPace
Jan 30, 2024
Initiates: Outperform
Price Target: $22
Current: $9.94
Upside: +121.33%
Insulet
Oct 16, 2023
Initiates: Outperform
Price Target: $184
Current: $330.84
Upside: -44.38%
Oct 16, 2023
Initiates: Outperform
Price Target: $42
Current: $31.68
Upside: +32.58%
Oct 16, 2023
Initiates: Outperform
Price Target: $342
Current: $438.72
Upside: -22.05%
Oct 16, 2023
Initiates: Market Perform
Price Target: $75
Current: $74.41
Upside: +0.79%
Oct 16, 2023
Initiates: Outperform
Price Target: $37
Current: $37.39
Upside: -1.04%
Oct 16, 2023
Initiates: Outperform
Price Target: $9
Current: $17.20
Upside: -47.67%
Aug 15, 2023
Downgrades: Market Perform
Price Target: $325 → $50
Current: $2.87
Upside: +1,645.20%
Jan 24, 2023
Maintains: Outperform
Price Target: $33 → $45
Current: $1.43
Upside: +3,046.85%
Dec 20, 2022
Maintains: Outperform
Price Target: $145 → $315
Current: $439.93
Upside: -28.40%
Dec 15, 2022
Maintains: Market Perform
Price Target: $26 → $31
Current: $49.13
Upside: -36.90%
Nov 4, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $14.78
Upside: -5.28%
Aug 15, 2022
Maintains: Outperform
Price Target: $32 → $40
Current: $19.43
Upside: +105.87%
Aug 11, 2022
Maintains: Outperform
Price Target: $392 → $384
Current: $19.86
Upside: +1,833.53%